Dr. Dubrovsky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd., NW
Washington, DC 20007Phone+1 202-444-7599
Summary
- Leonid Dubrovsky, MD, is a graduate of Jefferson University, College of Medicine. He completed his pediatric residency at Children’s National Medical Center and his hematology oncology fellowship at Memorial Sloan Kettering Cancer Center. Before joining the MedStar Georgetown staff as an assistant professor, Dr. Dubrovsky served on the Pediatric Hematology Oncology team at St. Jude Affiliate Clinic at Children’s Hospital in Baton Rouge.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Research, 2014 - 2015
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2011 - 2014
- Children's National HospitalResidency, Pediatrics, 2007 - 2010
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2007
- Thomas Jefferson UniversityMD, 2007
Certifications & Licensure
- LA State Medical License 2016 - Present
- DC State Medical License 2010 - 2022
- NY State Medical License 2011 - 2016
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 1 citationsA Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116.Masatoshi Kudo, Richard S Finn, Masafumi Ikeda, Max W Sung, Ari D Baron
Liver Cancer. 2024-08-01 - 73 citationsLenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.Josep M Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin
The Lancet. Oncology. 2023-12-01 - 46 citationsRandomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Am...Josep M Llovet, Arndt Vogel, David C Madoff, Richard S Finn, Sadahisa Ogasawara
Cardiovascular and Interventional Radiology. 2022-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: